NZ628392A - Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease - Google Patents

Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Info

Publication number
NZ628392A
NZ628392A NZ628392A NZ62839213A NZ628392A NZ 628392 A NZ628392 A NZ 628392A NZ 628392 A NZ628392 A NZ 628392A NZ 62839213 A NZ62839213 A NZ 62839213A NZ 628392 A NZ628392 A NZ 628392A
Authority
NZ
New Zealand
Prior art keywords
treatment
pulmonary disease
chronic obstructive
obstructive pulmonary
acute exacerbations
Prior art date
Application number
NZ628392A
Other languages
English (en)
Inventor
Paul Andrew Ford
Original Assignee
Mereo Biopharma 1 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 1 Ltd filed Critical Mereo Biopharma 1 Ltd
Publication of NZ628392A publication Critical patent/NZ628392A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ628392A 2012-03-20 2013-03-19 Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease NZ628392A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613187P 2012-03-20 2012-03-20
PCT/EP2013/055730 WO2013139809A1 (en) 2012-03-20 2013-03-19 Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
NZ628392A true NZ628392A (en) 2016-06-24

Family

ID=47901996

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628392A NZ628392A (en) 2012-03-20 2013-03-19 Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Country Status (29)

Country Link
US (2) US9339491B2 (enExample)
EP (1) EP2827860B1 (enExample)
JP (1) JP6091593B2 (enExample)
KR (1) KR101793777B1 (enExample)
CN (1) CN104203234B (enExample)
AU (1) AU2013237503B2 (enExample)
BR (1) BR112014023107B1 (enExample)
CA (1) CA2866108C (enExample)
CL (1) CL2014002471A1 (enExample)
CY (1) CY1118327T1 (enExample)
DK (1) DK2827860T3 (enExample)
ES (1) ES2605942T3 (enExample)
HR (1) HRP20161514T1 (enExample)
HU (1) HUE032004T2 (enExample)
IL (1) IL234537A (enExample)
LT (1) LT2827860T (enExample)
MA (1) MA37455B1 (enExample)
MX (1) MX351996B (enExample)
NZ (1) NZ628392A (enExample)
PH (1) PH12014502107B1 (enExample)
PL (1) PL2827860T3 (enExample)
PT (1) PT2827860T (enExample)
RU (1) RU2625762C2 (enExample)
SG (1) SG11201404941WA (enExample)
SI (1) SI2827860T1 (enExample)
TN (1) TN2014000350A1 (enExample)
TW (1) TWI583381B (enExample)
WO (1) WO2013139809A1 (enExample)
ZA (1) ZA201405871B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600833C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронической обструктивной болезни легких
RU2600822C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронического обструктивного бронхита
WO2017153702A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
US10617674B2 (en) 2016-03-08 2020-04-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
US10331542B2 (en) * 2016-06-23 2019-06-25 International Business Machines Corporation System and method for detecting and alerting unexpected behavior of software applications
GB201612238D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
KR102899004B1 (ko) * 2017-12-11 2025-12-12 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
CN114141383A (zh) * 2021-12-17 2022-03-04 湖南大学 慢阻肺智能护理方法、装置及系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HRP20161514T1 (hr) 2016-12-30
TWI583381B (zh) 2017-05-21
US20150031736A1 (en) 2015-01-29
MX351996B (es) 2017-11-06
CA2866108A1 (en) 2013-09-26
IL234537A (en) 2016-09-29
ZA201405871B (en) 2016-01-27
LT2827860T (lt) 2016-12-12
PH12014502107B1 (en) 2019-11-27
SI2827860T1 (sl) 2017-01-31
JP2015510916A (ja) 2015-04-13
MA37455B1 (fr) 2017-03-31
CY1118327T1 (el) 2017-06-28
EP2827860B1 (en) 2016-10-26
PT2827860T (pt) 2016-12-20
EP2827860A1 (en) 2015-01-28
PH12014502107A1 (en) 2014-12-10
CA2866108C (en) 2017-03-07
KR101793777B1 (ko) 2017-11-03
HK1200352A1 (en) 2015-08-07
US20160243081A1 (en) 2016-08-25
SG11201404941WA (en) 2014-10-30
TW201343162A (zh) 2013-11-01
KR20140146073A (ko) 2014-12-24
CN104203234B (zh) 2017-06-13
MX2014011291A (es) 2014-10-13
CN104203234A (zh) 2014-12-10
US9339491B2 (en) 2016-05-17
BR112014023107A2 (enExample) 2017-06-20
TN2014000350A1 (en) 2015-12-21
CL2014002471A1 (es) 2015-01-09
AU2013237503A1 (en) 2014-09-25
RU2625762C2 (ru) 2017-07-18
RU2014141893A (ru) 2016-05-10
BR112014023107B1 (pt) 2021-08-10
WO2013139809A1 (en) 2013-09-26
MA37455A1 (fr) 2016-08-31
DK2827860T3 (en) 2016-12-12
ES2605942T3 (es) 2017-03-17
PL2827860T3 (pl) 2017-09-29
HUE032004T2 (en) 2017-08-28
AU2013237503B2 (en) 2016-05-26
JP6091593B2 (ja) 2017-03-08

Similar Documents

Publication Publication Date Title
PH12014502107B1 (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MX2015016416A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
JP2015510916A5 (enExample)
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
HK1251998A1 (zh) 佐米曲普坦肺部给药粉
MX2015007488A (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib.
MX385717B (es) Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
HK1219728A1 (zh) 新型抗疟疾药剂
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease
CA2909448C (en) Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck
NZ724285A (en) Agent for improving or preventing progression of chronic kidney disease
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH

Effective date: 20150312

ASS Change of ownership

Owner name: MEREO BIOPHARMA 1 LIMITED, GB

Effective date: 20160526

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2018 BY CPA GLOBAL

Effective date: 20170203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2019 BY CPA GLOBAL

Effective date: 20180201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2020 BY CPA GLOBAL

Effective date: 20190201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2021 BY CPA GLOBAL

Effective date: 20200206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2022 BY CPA GLOBAL

Effective date: 20210204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2023 BY CPA GLOBAL

Effective date: 20220204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2024 BY CPA GLOBAL

Effective date: 20230202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2027 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20260205